Literature DB >> 28713670

In vitro experimental models of mesothelioma revisited.

Anand Singh1, Nathanael Pruett1, Chuong D Hoang1.   

Abstract

Malignant pleural mesothelioma (MPM) is a biologically unusual, highly aggressive cancer that defies current multimodality treatments. Epidemiologic data suggest that this malignancy has not abated despite increasingly strict environmental regulations on asbestos, the putative causative agent for sporadic cases. An incomplete understanding of all the factors mechanistically driving mesothelioma is largely responsible for the current lack of curative treatments. Many approaches have been employed to ascertain the step-by-step molecular events involved in mesothelioma oncogenesis including in vitro, small animal in vivo, and human experimental models; though clearly defined, druggable mechanisms still are elusive. Importantly, the foundation of the latest accepted model of tumor initiation is derived from in vitro systems. A thorough review of in vitro mesothelioma oncogenesis models may suggest further opportunities for discovery.

Entities:  

Keywords:  Mesothelioma; asbestos; in vitro; oncogenesis; transformation

Year:  2017        PMID: 28713670      PMCID: PMC5504106          DOI: 10.21037/tlcr.2017.04.12

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  72 in total

1.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Authors:  Matthew Bott; Marie Brevet; Barry S Taylor; Shigeki Shimizu; Tatsuo Ito; Lu Wang; Jenette Creaney; Richard A Lake; Maureen F Zakowski; Boris Reva; Chris Sander; Robert Delsite; Simon Powell; Qin Zhou; Ronglai Shen; Adam Olshen; Valerie Rusch; Marc Ladanyi
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

2.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

3.  Evidence against a role for SV40 in human mesothelioma.

Authors:  James J Manfredi; Jianli Dong; Wen-jun Liu; Lois Resnick-Silverman; Rui Qiao; Philippe Chahinian; Marko Saric; Allen R Gibbs; James I Phillips; J Murray; Charles W Axten; Robert P Nolan; Stuart A Aaronson
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

Review 4.  Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases.

Authors:  Sarah X L Huang; Marie-Claude Jaurand; David W Kamp; John Whysner; Tom K Hei
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

5.  Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008.

Authors:  S Jane Henley; Theodore C Larson; Manxia Wu; Vinicius C S Antao; Mary Lewis; Germania A Pinheiro; Christie Eheman
Journal:  Int J Occup Environ Health       Date:  2013 Jan-Mar

Review 6.  Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: Two faces of Janus?

Authors:  A A Shvedova; E R Kisin; D Porter; P Schulte; V E Kagan; B Fadeel; V Castranova
Journal:  Pharmacol Ther       Date:  2008-12-06       Impact factor: 12.310

Review 7.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

8.  Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk.

Authors:  Monica Amati; Marco Tomasetti; Laura Mariotti; Lucia Miria Tarquini; Matteo Valentino; Lory Santarelli
Journal:  Mutat Res       Date:  2008 Aug-Sep       Impact factor: 2.433

9.  Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Authors:  Andrea Sartore-Bianchi; Fabio Gasparri; Arturo Galvani; Linda Nici; James W Darnowski; Dario Barbone; Dean A Fennell; Giovanni Gaudino; Camillo Porta; Luciano Mutti
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

10.  Where is iron in erionite? A multidisciplinary study on fibrous erionite-Na from Jersey (Nevada, USA).

Authors:  Alessandro F Gualtieri; Nicola Bursi Gandolfi; Simone Pollastri; Kilian Pollok; Falko Langenhorst
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

View more
  8 in total

1.  MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.

Authors:  Anand Singh; Nisan Bhattacharyya; Abhishek Srivastava; Nathanael Pruett; R Taylor Ripley; David S Schrump; Chuong D Hoang
Journal:  Mol Ther       Date:  2019-06-04       Impact factor: 11.454

2.  Normal mesothelial cell lines newly derived from human pleural biopsy explants.

Authors:  Nathanael Pruett; Anand Singh; Ahjeetha Shankar; David S Schrump; Chuong D Hoang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-07-29       Impact factor: 5.464

Review 3.  New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

Authors:  Marika Rossini; Paola Rizzo; Ilaria Bononi; Anthony Clementz; Roberto Ferrari; Fernanda Martini; Mauro G Tognon
Journal:  Front Oncol       Date:  2018-04-03       Impact factor: 6.244

Review 4.  Mesotheliomas in Genetically Engineered Mice Unravel Mechanism of Mesothelial Carcinogenesis.

Authors:  Didier Jean; Marie-Claude Jaurand
Journal:  Int J Mol Sci       Date:  2018-07-27       Impact factor: 5.923

Review 5.  Mouse models for mesothelioma drug discovery and development.

Authors:  Kenneth P Seastedt; Nathanael Pruett; Chuong D Hoang
Journal:  Expert Opin Drug Discov       Date:  2020-12-31       Impact factor: 7.050

6.  Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.

Authors:  Sabrina Borchert; Michael Wessolly; Jan Schmeller; Elena Mairinger; Jens Kollmeier; Thomas Hager; Thomas Mairinger; Thomas Herold; Daniel C Christoph; Robert F H Walter; Wilfried E E Eberhardt; Till Plönes; Jeremias Wohlschlaeger; Clemens Aigner; Kurt Werner Schmid; Fabian D Mairinger
Journal:  BMC Cancer       Date:  2019-01-30       Impact factor: 4.430

7.  Double-Stranded RNA Structural Elements Holding the Key to Translational Regulation in Cancer: The Case of Editing in RNA-Binding Motif Protein 8A.

Authors:  Asra Abukar; Martin Wipplinger; Ananya Hariharan; Suna Sun; Manuel Ronner; Marika Sculco; Agata Okonska; Jelena Kresoja-Rakic; Hubert Rehrauer; Weihong Qi; Victor W van Beusechem; Emanuela Felley-Bosco
Journal:  Cells       Date:  2021-12-15       Impact factor: 6.600

8.  Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior.

Authors:  Alexander Mathilakathu; Michael Wessolly; Elena Mairinger; Hendrik Uebner; Daniel Kreidt; Luka Brcic; Julia Steinborn; Kristina Greimelmaier; Jeremias Wohlschlaeger; Kurt Werner Schmid; Fabian D Mairinger; Sabrina Borchert
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.